Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Straße 22, 81675, Munich, Germany.
Institute for Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Neuherberg, Germany.
Strahlenther Onkol. 2021 Nov;197(11):962-970. doi: 10.1007/s00066-020-01738-1. Epub 2021 Jan 27.
Emerging moderately hypofractionated and ultra-hypofractionated schemes for radiotherapy (RT) of prostate cancer (PC) have resulted in various treatment options. The aim of this survey was to evaluate recent patterns of care of German-speaking radiation oncologists for RT of PC.
We developed an online survey which we distributed via e‑mail to all registered members of the German Society of Radiation Oncology (DEGRO). The survey was completed by 109 participants between March 3 and April 3, 2020. For evaluation of radiation dose, we used the equivalent dose at fractionation of 2 Gy with α/β = 1.5 Gy, equivalent dose (EQD2 [1.5 Gy]).
Median EQD2(1.5 Gy) for definitive RT of the prostate is 77.60 Gy (range: 64.49-84.00) with median single doses (SD) of 2.00 Gy (range: 1.80-3.00), while for postoperative RT of the prostate bed, median EQD2(1.5 Gy) is 66.00 Gy (range: 60.00-74.00) with median SD of 2.00 Gy (range: 1.80-2.00). For definitive RT, the pelvic lymph nodes (LNs) are treated in case of suspect findings in imaging (82.6%) and/or according to risk formulas/tables (78.0%). In the postoperative setting, 78.9% use imaging and 78.0% use the postoperative tumor stage for LN irradiation. In the definitive and postoperative situation, LNs are irradiated with a median EQD2(1.5 Gy) of 47.52 Gy with a range of 42.43-66.00 and 41.76-62.79, respectively.
German-speaking radiation oncologists' patterns of care for patients with PC are mainly in line with the published data and treatment recommendation guidelines. However, dose prescription is highly heterogenous for RT of the prostate/prostate bed, while the dose to the pelvic LNs is mainly consistent.
新兴的中度适形和超适形前列腺癌放射治疗（RT）方案导致了各种治疗选择。本研究的目的是评估德国讲德语的放射肿瘤学家对前列腺癌 RT 的治疗模式。
我们开发了一个在线调查，通过电子邮件分发给德国放射肿瘤学会（DEGRO）的所有注册成员。2020 年 3 月 3 日至 4 月 3 日，109 名参与者完成了这项调查。为了评估辐射剂量，我们使用了 α/β=1.5Gy 时的 2Gy 分割等效剂量，即等效剂量（EQD2[1.5Gy]）。
前列腺根治性 RT 的中位 EQD2（1.5Gy）为 77.60Gy（范围：64.49-84.00），单次剂量（SD）中位数为 2.00Gy（范围：1.80-3.00），而前列腺床术后 RT 的中位 EQD2（1.5Gy）为 66.00Gy（范围：60.00-74.00），SD 中位数为 2.00Gy（范围：1.80-2.00）。对于根治性 RT，如果影像学检查有可疑发现（82.6%）和/或根据风险公式/表（78.0%），则治疗骨盆淋巴结（LNs）。在术后环境中，78.9%使用影像学和 78.0%使用术后肿瘤分期进行 LN 照射。在根治性和术后情况下，LN 照射的中位 EQD2（1.5Gy）分别为 47.52Gy（范围：42.43-66.00）和 41.76Gy（范围：41.76-62.79）。
德语区放射肿瘤学家对 PC 患者的治疗模式主要与已发表的数据和治疗建议指南一致。然而，前列腺/前列腺床 RT 的剂量处方差异很大，而骨盆 LNs 的剂量则主要一致。
